Latest Foreign Investment Review News

Global Uranium and Enrichment Limited has obtained a crucial ASX waiver allowing the cancellation of certain unlisted options without shareholder approval, smoothing the path for Snow Lake Resources’ acquisition scheme.

TPC Consolidated’s proposed acquisition by Wollar Holding Ltd hits a regulatory snag as FIRB approval misses the November 28 sunset deadline, casting uncertainty over the deal’s future.

Urenco Limited has secured Foreign Investment Review Board approval for its strategic investment in Ubaryon, where Global Uranium and Enrichment Limited holds a significant stake, marking a key milestone in advancing innovative uranium enrichment technology.

National Storage REIT has received a conditional, non-binding proposal from a Brookfield and GIC consortium to acquire all stapled securities at $2.86 each, triggering an exclusivity period for negotiations.

Invictus Energy updates progress on its AMOG joint venture with Al Mansour Holdings, revealing ongoing negotiations for a significant Qatari ownership stake and deferral of a key placement settlement.

Entertainment Rewards Ltd has issued a Target’s Statement recommending shareholders accept Suzerain Investment Holdings’ conditional off-market takeover offer at a significant premium. An independent expert concurs the offer is fair and reasonable, setting the stage for potential full ownership by Suzerain.

Macquarie Asset Management has tabled a $5.20 per share cash offer to acquire Qube Holdings, valuing the logistics giant at approximately $11.6 billion. The Qube board has entered an exclusivity agreement and signals unanimous support, pending due diligence and regulatory approvals.

The Foreign Investment Review Board has formally objected to Cosette Pharmaceuticals’ proposed acquisition of Mayne Pharma, casting serious doubt on the deal’s future and prompting Mayne to explore alternative paths.

Northern Minerals has applied to defer its 2025 AGM as it awaits regulatory review over potential foreign investment breaches, underscoring heightened scrutiny on shareholder compliance.

Mayne Pharma’s acquisition by Cosette Pharmaceuticals faces a brief delay as FIRB extends its approval deadline, prompting a reschedule of the critical court hearing to November 23.

The Takeovers Panel has declared unacceptable circumstances in the Mayne Pharma acquisition, ordering Cosette Pharmaceuticals to comply with conditions preventing closure of the Salisbury manufacturing site. This ruling highlights concerns over market transparency and the integrity of the takeover process.

The Takeovers Panel has declared unacceptable circumstances in the Mayne Pharma acquisition after Cosette Pharmaceuticals changed its intentions to close the Salisbury manufacturing site, raising concerns over market transparency and regulatory approval.